✦ LIBER ✦

Non-antibody immunotherapy of cancer

✍ Scribed by Paul B. Chapman; Alan N. Houghton

Publisher: Elsevier Science
Year: 1993
Tongue: English
Weight: 704 KB
Volume: 5
Category: Article
ISSN: 0952-7915
DOI: 10.1016/0952-7915(93)90128-f

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Idiotypic antibody immunotherapy of canc

Idiotypic antibody immunotherapy of cancer

✍ Malaya Bhattacharya Chatterjee; Kenneth A. Foon; Heinz Köhler 📂 Article 📅 1994 🏛 Springer-Verlag 🌐 English ⚖ 1010 KB

Immunotherapy of pancreatic cancer with

Immunotherapy of pancreatic cancer with monoclonal antibody BW 494

✍ G. Schulz; M. Büchler; K. H. Muhrer; R. Klapdor; R. Kübel; H. P. Harthus; N. Mad 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 French ⚖ 593 KB

In a phase I trial 34 patients with pancreatic cancer were treated with the murine monoclonal antibody (MAb) BW 494 (BI 51.011) directed against a glycoprotein antigen. The patients received repeated doses of MAb over a time period from 5 to 14 days (highest single dose 100 mg, highest cumulative do

Immunotherapy of cancer

✍ Franco M. Muggia 📂 Article 📅 1977 🏛 Springer-Verlag 🌐 English ⚖ 464 KB

Isotopic immunotherapy: radiolabelled an

Isotopic immunotherapy: radiolabelled antibody

✍ Stanley E. Order 📂 Article 📅 1988 🏛 Elsevier Science 🌐 English ⚖ 610 KB

Principles and use of anti-CTLA4 antibod

Principles and use of anti-CTLA4 antibody in human cancer immunotherapy

✍ Karl S Peggs; Sergio A Quezada; Alan J Korman; James P Allison 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 416 KB

Cytotoxic T lymphocyte antigen-4 has become recognized as one of the key negative regulators of adaptive immune responses, having a central role in the maintenance of peripheral tolerance and in shaping the repertoire of emergent T cell responses. Concurrent recognition of the potential importance o

Immunotherapy of bladder cancer

✍ Unyime O. Nseyo; Donald L. Lamm 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 48 KB 👁 2 views

Intravesical therapy has been used in the management of superficial transitional cell carcinoma (TCC) of the urinary bladder (i.e., Ta, Tl, and carcinoma in situ) with specific objectives which include treating existing/residual tumor, preventing recurrence of tumor, preventing disease progression,